NextCure (NASDAQ:NXTC) Stock Rating Upgraded by Wall Street Zen

NextCure (NASDAQ:NXTC) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating on shares of NextCure in a research report on Thursday. Weiss Ratings raised shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Finally, Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Price Performance

Shares of NXTC stock opened at $8.21 on Friday. The company has a market capitalization of $29.64 million, a PE ratio of -0.94 and a beta of 1.26. The firm’s 50-day moving average is $3.80 and its two-hundred day moving average is $8.21. NextCure has a 12 month low of $1.55 and a 12 month high of $15.74.

NextCure (NASDAQ:NXTC) last released its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85). Sell-side analysts forecast that NextCure will post -8.11 EPS for the current year.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc purchased 36,303 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $4.94 per share, for a total transaction of $179,336.82. Following the purchase, the insider directly owned 722,419 shares of the company’s stock, valued at $3,568,749.86. This represents a 5.29% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders bought 346,761 shares of company stock valued at $1,710,807. 11.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On NextCure

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in NextCure in the 4th quarter valued at $160,000. Millennium Management LLC acquired a new stake in shares of NextCure in the 4th quarter valued at approximately $185,000. Geode Capital Management LLC raised its position in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after acquiring an additional 3,636 shares in the last quarter. Cable Car Capital LP lifted its holdings in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.